Clinical and biological features of study patients
| Characteristic . | MDS N = 70 . |
|---|---|
| Age, median (range), y | 81 (54-94) |
| Male, n (%) | 51 (72.9) |
| Female, n (%) | 19 (27.1) |
| Hemoglobin, median (range), g/dL | 11.75 (7.6-17.8) |
| WBC count, median (range), ×109/L | 4.58 (1.44-12.28) |
| Neutrophil count, median (range), ×109/L | 2.41 (0.31-7.68) |
| Platelet count, median (range), ×109/L | 154 (28-584) |
| Presence PB blasts, n (%) | 2 (2.86) |
| LDH, median (range) | 292 (111-487) |
| BM blasts %, median (range) | 2 (0-19) |
| RSs %, median (range) | 0 (0-90) |
| Altered karyotype, n (%) | 20 (28.6) |
| Very good cytogenetic IPSS-R risk group, n (%) | 6 (8.6) |
| Good cytogenetic IPSS-R risk group, n (%) | 7 (10) |
| Intermediate cytogenetic IPSS-R risk group, n (%) | 4 (5.7) |
| Poor cytogenetic IPSS-R risk group, n (%) | 2 (2.9) |
| Very poor cytogenetic IPSS-R risk group, n (%) | 1 (1.4) |
| IPSS-R risk group | |
| Very low, n (%) | 28 (40) |
| Low, n (%) | 31 (44.3) |
| Intermediate, n (%) | 7 (10) |
| High, n (%) | 2 (2.9) |
| Very high, n (%) | 2 (2.9) |
| MDS subtype (WHO 2017) | |
| MDS-SLD, n (%) | 1 (1.4) |
| MDS-MLD, n (%) | 35 (50) |
| MDS-RS-SLD, n (%) | 5 (7.1) |
| MDS-RS-MLD, n (%) | 17 (24.3) |
| MDS-del(5q), n (%) | 2 (2.9) |
| MDS-EB-1, n (%) | 6 (8.6) |
| MDS-EB-2, n (%) | 2 (2.9) |
| MDS-U, n (%) | 2 (2.9) |
| Number of patients with mutations, n (%) | 66 (94.3) |
| Mutations per patient, median (range) | 3 (0-10) |
| Mutated genes per patient, median (range) | 2 (0-6) |
| cfDNA concentration, median (range), ng/plasma mL | 58.4 (10.6-91.4) |
| Characteristic . | MDS N = 70 . |
|---|---|
| Age, median (range), y | 81 (54-94) |
| Male, n (%) | 51 (72.9) |
| Female, n (%) | 19 (27.1) |
| Hemoglobin, median (range), g/dL | 11.75 (7.6-17.8) |
| WBC count, median (range), ×109/L | 4.58 (1.44-12.28) |
| Neutrophil count, median (range), ×109/L | 2.41 (0.31-7.68) |
| Platelet count, median (range), ×109/L | 154 (28-584) |
| Presence PB blasts, n (%) | 2 (2.86) |
| LDH, median (range) | 292 (111-487) |
| BM blasts %, median (range) | 2 (0-19) |
| RSs %, median (range) | 0 (0-90) |
| Altered karyotype, n (%) | 20 (28.6) |
| Very good cytogenetic IPSS-R risk group, n (%) | 6 (8.6) |
| Good cytogenetic IPSS-R risk group, n (%) | 7 (10) |
| Intermediate cytogenetic IPSS-R risk group, n (%) | 4 (5.7) |
| Poor cytogenetic IPSS-R risk group, n (%) | 2 (2.9) |
| Very poor cytogenetic IPSS-R risk group, n (%) | 1 (1.4) |
| IPSS-R risk group | |
| Very low, n (%) | 28 (40) |
| Low, n (%) | 31 (44.3) |
| Intermediate, n (%) | 7 (10) |
| High, n (%) | 2 (2.9) |
| Very high, n (%) | 2 (2.9) |
| MDS subtype (WHO 2017) | |
| MDS-SLD, n (%) | 1 (1.4) |
| MDS-MLD, n (%) | 35 (50) |
| MDS-RS-SLD, n (%) | 5 (7.1) |
| MDS-RS-MLD, n (%) | 17 (24.3) |
| MDS-del(5q), n (%) | 2 (2.9) |
| MDS-EB-1, n (%) | 6 (8.6) |
| MDS-EB-2, n (%) | 2 (2.9) |
| MDS-U, n (%) | 2 (2.9) |
| Number of patients with mutations, n (%) | 66 (94.3) |
| Mutations per patient, median (range) | 3 (0-10) |
| Mutated genes per patient, median (range) | 2 (0-6) |
| cfDNA concentration, median (range), ng/plasma mL | 58.4 (10.6-91.4) |
EB, excess blasts; LDH, lactate dehydrogenase; MLD, multilineage dysplasia; SLD, single lineage dysplasia; U, unclassifiable; WBC, white blood cells; WHO, World Health Organization.